PRMT1 Stabilizes Proteins That Drive Liver Regeneration
A newly published study identifies the enzyme PRMT1 as a key regulator of cell proliferation during liver repair.
Updated on Nov. 1, 2026 in Life Sciences
Live Poll
Do you think new liver disease treatments are coming soon enough to help you?
Researchers report that PRMT1 methylates SKP1 at residue R81, blocking the FBXW7-mediated breakdown of pro-proliferative phosphoproteins needed for liver cells to divide. The accepted article was published early on nature.com on 2026-11-01.
Why it matters
Liver regeneration depends on tightly controlled cell division, and identifying the molecular switch that protects growth-promoting proteins clarifies how the organ repairs itself. The findings also point to PRMT1 as a candidate target for liver diseases in which regeneration is impaired.
The evidence is an accepted peer-reviewed article reporting in vivo results in mice and patients showing S-adenosylmethionine accelerates liver regeneration versus untreated controls. Quantitative effect sizes and sample sizes are not stated in the extraction, and whether PRMT1 inhibition or activation would produce the same effect in patients remains untested.
The details
PRMT1 is upregulated by epidermal growth factor through receptor tyrosine kinase signaling and catalyzes asymmetric dimethylation of SKP1 at R81. That modification disrupts FBXW7 recruitment to the SCF E3 ubiquitin ligase complex, preventing ubiquitination of target phosphoproteins during hepatocyte proliferation.
Timeline
• 2026-11-01: Accepted research article published early on nature.com.
Big Picture
The work extends the established SCF E3 ligase pathway, in which FBXW7 recognizes and tags proteins for degradation, by showing that PRMT1-driven methylation of SKP1 at R81 blocks FBXW7 recruitment. This adds a post-translational control layer to a pathway already known to govern cell cycle proteins.
Any therapy built on this mechanism would be years from clinical use, since the extraction reports only preclinical and early patient-level findings. For now, the result is a research direction rather than a treatment readers can access.
The takeaway
Liver regeneration relies on molecular brakes that protect growth-promoting proteins from degradation, and PRMT1 has emerged as one such regulator. Tracking follow-up studies will show whether targeting it can safely support liver repair.
Further reading
Explore more Life Sciences research on how cells control growth and repair.
Source note: This article includes information reported by Nature.
Live Poll
Do you think new liver disease treatments are coming soon enough to help you?
